ZyVersa Therapeutics, Inc.
ZVSA· OTC
ZVSAZyVersa Therapeutics, Inc.
Filed May 13, 2026 · 10-Q · 43 days after period end · 0001493152-26-022759
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$1.79M | -$2.26M | -$2.83M | -$3.54M |
| EPS Diluted | -$0.22 | -$0.73 | -$4.53 | -$135.88 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end
